Chinmaya Rath
Corporate Officer/Principal chez GLYCOMIMETICS, INC.
Fortune : 43 679 $ au 31/05/2024
Postes actifs de Chinmaya Rath
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Corporate Officer/Principal | - | - |
Catena Biosciences, Inc.
 Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Directeur/Membre du Conseil | - | - |
| Cellurx | Directeur Général | - | - |
| Fondateur | - | - | |
Social Impact Capital, Inc.
 Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | Private Equity Investor | 01/11/2022 | - |
Historique de carrière de Chinmaya Rath
Formation de Chinmaya Rath
| Warwick Business School | Masters Business Admin |
| Ravenshaw University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 2 |
| Inde | 2 |
Opérationnelle
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Commercial Services |
| Cellurx | |
Social Impact Capital, Inc.
Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | Finance |
- Bourse
- Insiders
- Chinmaya Rath
- Expérience
